#USA #Fremont #Alamar Biosciences #NULISAseq #Inflammation Panel

Alamar Biosciences Introduces NULISAseq Inflammation Panel AQ

Alamar Biosciences has recently unveiled a groundbreaking product, the NULISAseq Inflammation Panel AQ, designed to set new standards in immune response profiling within clinical and longitudinal studies. This innovative panel promises unparalleled coverage and precision, enabling researchers to discover new disease progression signatures and therapeutic responses through absolute quantitative measurements of over 150 key protein biomarkers obtained from a single sample.

The NULISAseq Inflammation Panel AQ stands out due to its exceptional sensitivity, which allows for the detection of cytokine levels in both healthy and diseased states. This capability provides a robust platform for tracking immune changes relative to baseline measurements or post-therapeutic interventions within clinical cohorts. In essence, this cutting-edge solution redefines precision in biomarker discovery and clinical research.

Key Features and Benefits of the NULISAseq Inflammation Panel AQ

• - Unmatched Sensitivity: Offering a quantifiability exceeding 99% in normal samples, this panel enables researchers to detect subtle changes in immune responses, supporting a more accurate monitoring of immunological reactions.
• - Broad Dynamic Range: With a range of over 9 logs, the panel allows for the simultaneous quantification of high and low-abundance proteins from the same sample, ensuring comprehensive data collection.
• - High Reproducibility: A coefficient of variation (CV) below 10% ensures consistent, reliable results, even in extensive clinical studies.

Yuling Luo, Chairman and CEO of Alamar Biosciences, remarked, "The NULISAseq Inflammation Panel AQ represents the largest available panel for absolute quantification and marks a significant advancement in precision proteomics. Its unparalleled sensitivity and dynamic range empower researchers to push the boundaries of immunological research, ultimately enhancing our understanding of health and disease."

The technology behind the NULISAseq Inflammation Panel AQ is rooted in Alamar’s proprietary NULISA™ technology. This highly specialized approach integrates a patented sequential immune complex capture and release mechanism with next-generation sequencing, facilitating multiplex, highly sensitive protein analysis. Additionally, the panel requires only 25μl of input, making it particularly suitable for oncology applications, as well as studies related to autoimmune and infectious diseases where sample amounts may be limited.

Interested parties can learn more about the NULISAseq Inflammation Panel AQ by visiting Alamar Biosciences' website.

About Alamar Biosciences

Alamar Biosciences is a private biotechnology firm focused on advancing precision proteomics to enable the early detection of diseases. Their proprietary NULISA™ Platform and ARGO™ HT System seamlessly integrate with the latest advancements in genomics, achieving detection sensitivity in the attomolar range, significantly surpassing any currently available protein detection technology on the market. For further details, please visit Alamar Biosciences.